Keterbatasan Penelitian Hasil dan Pembahasan
62 12.
Nurman A, Huang MA. Perlemakan Hati Non Alkoholik. Universa Medicina.2007;264:205-15.
13. Neuschwander-Tetri BA. Nonalcoholic Steatohepatitis and the Metabolic
Syndrome. Am J Med Sci.2005;3306:326-335 14.
Podolsky Daniel K.. Infiltrative, Genetic, and Metabolic Diseases Affecting the Liver. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL,
Jameson JL eds.Harrison’s Principles of Internal Medicine. 16th ed. USA: McGraw-Hill; 2005. p1869-71
15. Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The Epidemiology of Fatty
Liver. European
Journal of
Gastroenterology Hepatology.2004;1611:1087-1093.
16. Lim JS, Snyder MM, Valente A, Schwarz JM, Lustig RH. The role of
Fructose in the Pathogenesis of NAFLD and the Metabolic Syndrome. Nat. Rev. Gastroenterol. Hepatol..2010;70:251-264
17. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic
fatty liver disease. QJ Med.2010;1030:71-83 A
18. Kuntz E. Hepatology Principles and Practice. 2nd ed. Germany. Springer;
2006 19.
Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in Nonalcoholic Fatty Liver Disease: Not All Lipids Are Created Equal. Expert Rev Gastroenterol
Hepatol.2009;34:445-451 20.
Peverill W, Powell LW, Skolen R. Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation. Int. J. Mol. Sci..2014;150:8591-
8638 21.
Wieckowska A, Feldstein AE. Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive. Seminars in Liver Disease.2008;284:386-395
22. National Intitutes of Health NIH. Nonalcoholic Steatohepatitis: 2006
23. Miskovitz P, Betancourt M. The Doctors Guide to Gastrointestinal Health. 1st
ed. USA. John Wiley Sons, Inc.; 2005 24.
Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: A Practical
Approach to
Diagnosis and
Staging. Frontline
Gastroenterology.2014;50:211-218 25.
Treeprasertsuk S, Björnsson
E, Enders Felicity, Suwanwalaikom S, Lindor KD.NAFLD fibrosis score: A Prognostic Predictor for Mortality and Liver
63 Complications
among NAFLD
Patients. World
Journal of
Gastroenterology.2013;198:1219-1229 26.
Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease. Semin Liv Dis.2012;321:22-29
27. McCance KL, Huether SE, Brashers SE, Rote NS. Pathophysiology the
Biologic Basis for Disease in Adults and Children. 6th ed. United States of America. Elsevier; 2010
28. Tortora GJ, Derrickson B. Principles of Anatomy Physiology. 13th ed.
United States of America. John Wiley Sons, Inc.; 2012 29.
Kamso S, Purwantyastuti, Juwita R. Dislipidemia Pada Lanjut Usia di Kota Padang. Makara Kesehatan.2002;62:55-58
30. Hatma RD. Lipid Profiles Among Diverse Ethnic Groups in Indonesia. Acta
Med Indones-Indones J Intern Med.2011;431:4-11 31.
Garg A. Insulin Resistance in the Pathogenesis of Dyslipidemia. Diabetes Care.1996;194:387-389
32. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of
Dyslipidaemia in the Metabolic Syndrome. Postgrad Med J.2005;810:358- 366
33. National Institutes of Healt NIH. ATP III Guidelines At-A-Glance Quick
Desk Reference:2001 34.
Recommendations for the diagnosis and treatment of dyslipidemia. Can J Cardiol.2009;2211:1-5
35. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW,
etal. American Association of Clinical Endrocrinologists Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. AACE Lipid
and Atherosclerosis Guidelines, Endocr Pract..2012;180:1-78 36.
Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-Alcoholic Fatty Liver Disease NAFLD and Its Connection with
Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease. Nutrients.2013;50:1544-1560
37. Souza MRDA, Diniz MDFFDM, Medeiros-Filho JEMD, Araujo MSTD .
Metabolic Syndrome and Risk Factors for Non-Alcoholic Fatty Liver Disease. jan. Imar..2012;491:89-96